NCT06371001 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Hata K, Koyama T, Ozaki E, Kuriyama N, Mizuno S, Matsui D, Watanabe I, Uehara R, Watanabe Y
Assessing the Relationship between Helicobacter pylori and Chronic Kidney Disease. Healthcare (Basel). 2021 Feb 3;9(2):162. doi: 10.3390/healthcare9020162.
Lin SY, Lin CL, Liu JH, Yang YF, Huang CC, Kao CH
Association between Helicobacter pylori infection and the subsequent risk of end-stage renal disease: a nationwide population-based cohort study. Int J Clin Pract. 2015 May;69(5):604-10. doi: 10.1111/ijcp.12602. Epub 2015 Jan 21.
Shin SP, Bang CS, Lee JJ, Baik GH
Helicobacter pylori Infection in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Gut Liver. 2019 Nov 15;13(6):628-641. doi: 10.5009/gnl18517.
Zizzi CF, Pellicano R, Biancone L
The relationship between Helicobacter pylori and chronic kidney disease: update 2020. Minerva Gastroenterol Dietol. 2020 Dec;66(4):343-349. doi: 10.23736/S1121-421X.20.02729-4. Epub 2020 Jul 3.

Prevalance Of Helicobacter Pylori Infection In Chonic Kidney Diseased Patient Admitted To Luxor Medical

Clinical trial NCT06371001 - References